Kyowa Kirin USA Holdings, Inc.
Basic information
- Head office
- 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, Otemachi Financial City Gran Cube
- Chief executive
- Abdul Malik
- Capital
- 26,745,000,000 JPY (267 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- 5,161 people
- Start date
- 1949-07-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Kirin Brewery of America, LLC | ||||||||
|
|
||||||||
| Kyowa Kirin CA | ||||||||
| Kyowa Kirin Pharmaceutical Development | ||||||||
| Kyowa Kirin Pharmaceutical Research | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Kirin Echo Co., Ltd. | ||||||||
|
|
||||||||
| Kyowa Kirin Co., Ltd. (Korea) |
Network
History
The predecessor of Japan Brewery Company, Japan Brewery Company (hereafter JBC), was established. Later, T.B. Graber also served as an executive.![]()
JBC signed a sales agreement with Meijiya's Isano Kei and released a German-style lager beer under the brand name "Kirin Beer".![]()
Dr. Shibasaburo Kitasato and Dr. Bering discovered that the serum obtained from an animal infected with diphtheria was effective in the treatment of diphtheria and tetanus; they established serum therapy.![]()
Acquisition agreement with Toyo Brewing Co., Ltd. finalized; Sendai Factory (now Kirin Beer Sendai Factory) launched.![]()
Kirin Brewery changed its head office registration from Yokohama City Yamanote-cho to Yokohama City Kanagawa-ku Koayama-cho, Kaidai-dori.![]()
Kirin Beer terminated the exclusive sales agreement with Meijiya, established a sales department, and began sales.![]()
Kirin Beer changed the registered headquarters location from 1-1 Kaido-dori, Koayama-cho, Kanagawa-ku, Yokohama City to Ikimaki, Tsurumi-ku, Yokohama City.![]()
Kirin Beer completed a pharmaceutical plant within the Yokohama factory, producing yeast agents and the like.![]()
Manchuria Beer Co., Ltd. was established through joint investment with Dai Nippon Beer (business transferred in 1937).![]()
Reorganized the Harutori Transport Company, which handled logistics for Kirin Beer Yokohama Factory, into Harutori Automobile Transport Co., Ltd. (now Kirin Group Logistics Co., Ltd.)![]()
Kirin Beer opened the Kirin Research Institute (now Kirin Holdings Co., Ltd. Kirin Central Research Institute, etc.).![]()
Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.![]()
Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).![]()
Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first).![]()
Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.![]()
César Milstein, Georges Köhler and Niels Kaj Jerne established the hybridoma technology, which is a technology for producing monoclonal antibodies.![]()
The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.![]()
Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).![]()
Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.![]()
The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug. Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary. Capital alliance between Kyowa Hakko Group and Kirin Group.![]()
Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.![]()
Kirin Holdings Co., Ltd. and Kokura Dairy Co., Ltd. discovered a lactobacillus that activates immune cells responsible for virus infection defense (later named 'Plasma Lactobacillus').![]()
ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.![]()
Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan.![]()
Actively strengthening corporate governance that supports management, and continuing further improvements to date.![]()
In line with the new KV2021 policy, we sold Kirin Brazil Co., which had been experiencing declining performance.![]()
We launched a new brand featuring the group’s proprietary ingredient, ‘plasma lactic acid bacteria’. In 2020, it was the first functional food to receive approval for immune function, and sales continue to grow.![]()
Crysvita® approved in the US and Europe for X-linked hypophosphatemia. Poteligeo® approved in the US and Europe for mycosis fungoides (MF) and Sézary syndrome (SS).![]()
Trade name changed to Kyowa Kirin Co., Ltd. Crysvita® launched in Japan for FGF23-related Hypophosphatemic Rickets and Osteomalacia. Nourianz™ launched in the US for Parkinson's disease.![]()
Kirin Holdings established a new site, the iMUSE Health Science Factory, for manufacturing lactic acid bacteria raw materials, and began production.![]()
In the health science field, we partnered with FANCL to supplement capabilities not present in the group.![]()
Poteligeo® launched in Europe for mycosis fungoides (MF) and Sézary syndrome (SS). Crysvita® approved in the US for tumor-induced osteomalacia (TIO).![]()
The claim ‘supporting the maintenance of immune function in healthy individuals’ was the first time the consumer agency accepted a submission under the functional food labeling system.![]()
New Vision toward 2030. Agreement with Amgen on KHK4083 development. Support for TCFD recommendations.![]()
Global DE&I Statement adopted. Launch of G-Lasta® Subcutaneous Injection 3.6 mg BodyPod in Japan. Completion of Q-TOWER analysis facility.![]()
Aiming to become a leading health science company in Asia‑Pacific, we made the Australian company Blackmores, which operates in supplements and health foods, a subsidiary.![]()
Lenmeldy™ approved and launched in the US. New biologics manufacturing plant planned in North Carolina. Collaboration with Kura Oncology on menin inhibitor ziftomenib.![]()
Completion of HB7 Building at Takasaki Plant. FDA approval and US launch of KOMZIFTI™ (ziftomenib) for AML.![]()
Leveraging organizational capabilities cultivated across diverse business areas, we formulated the new long‑term management concept ‘Innovate2035!’ to sustain growth for the next 100 years through autonomous business growth and synergistic use of group assets. Our vision is to ‘keep the world healthier by continuously innovating as a CSV‑leading company powered by people and technology,’ and we are working toward realizing this.![]()
News
There is no news.